You are here

  • Home
  • Archive
  • Volume 66, Issue 3
  • Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome

Article info

Article menu
Download PDFPDF
Extended report
Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome

Authors

  1. Correspondence to:
    Professor X Mariette
    Service de Rhumatologie, Hôpital de Bicêtre, 78 rue du Général Leclerc, 94275 Le Kremlin Bicêtre, France; xavier.mariette{at}bct.ap-hop-paris.fr
View Full Text

Citation

Seror R, Sordet C, Guillevin L, et al
Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome
Annals of the Rheumatic Diseases 2007;66:351-357.

Publication history

  • Accepted August 25, 2006
  • First published September 1, 2006.
Online issue publication 
October 25, 2017

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Copyright 2007 by Annals of the Rheumatic Diseases